Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer
January 4th 2020
Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.